文献速递湿疹皮炎与荨麻疹

产IL-17A的固有淋巴样细胞通过诱导IL-33驱动的2型免疫反应促进皮肤炎症

IL-17A-Producing Innate Lymphoid Cells Promote Skin Inflammation by Inducing IL-33-Driven Type 2 Immune Responses.
PubMed 文献 · J Invest Dermatol · 2019-10-16

该研究探讨产IL-17A的3型固有淋巴样细胞(ILC3)在特应性皮炎(AD)发病中的作用。小鼠AD模型中皮肤ILC3数量增加,中和IL-17A可延缓AD发展,过继转移ILC3加速症状;机制上ILC3诱导角质形成细胞和成纤维细胞产生IL-33,促进2型免疫反应。

要点

  • AD小鼠皮肤中ILC3数量增加,中和IL-17A可延缓AD发展。
  • 过继转移ILC3可加速AD症状。
  • ILC3通过诱导非免疫皮肤细胞产生IL-33促进2型免疫反应。

核心结论

  • 产IL-17A的ILC3通过诱导非免疫皮肤细胞产生IL-33驱动2型免疫反应,促进AD皮肤炎症。

研究设计与样本

  • 研究采用AD诱导小鼠模型,检测皮肤ILC3数量,并进行IL-17A中和及ILC3过继转移实验。

主要发现

  • AD诱导小鼠皮肤中ILC3数量增加。
  • 中和IL-17A延迟AD发展,过继转移ILC3加速AD症状。
  • ILC3诱导角质形成细胞和成纤维细胞产生IL-33,促进2型免疫反应。

临床怎么用

  • 提示IL-17A及ILC3-IL-33轴可能作为AD的潜在干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease characterized by type 2 cytokines secreted by T helper type 2 cells and group 2 innate lymphoid cells. Despite a high degree of heterogeneity, AD is still explained by type 2 immunity, and the role of IL-17A, which is increased in acute, pediatric, or Asian patients with AD, remains poorly understood. Here, we aimed to investigate the role of IL-17A-producing group 3 innate lymphoid cells (ILC3s), which are unexplored immune cells, in the pathogenesis of AD. We found that the numbers of ILC3s in the skin of AD-induced mice were increased, and that neutralizing IL-17A delayed development of AD. Moreover, adoptive transfer of ILC3s accelerated the symptoms of AD. Mechanically, ILC3s induced IL-33 production by nonimmune skin cells, keratinocytes, and fibroblasts, which promoted type 2 immune responses. Because AD has a complex pathophysiology and a broad spectrum of clinical phenotypes, the presence of ILC3s in the skin and their interaction with nonimmune skin cells could explain the pathogenesis of cutaneous AD.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Kim MH, Jin SP, Jang S, et al. IL-17A-Producing Innate Lymphoid Cells Promote Skin Inflammation by Inducing IL-33-Driven Type 2 Immune Responses. J Invest Dermatol. 2019. PMID: 31628929. doi:10.1016/j.jid.2019.08.447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。